Abstract
Objective
Pentoxifylline (PTF) has anti-inflammatory properties, which may be beneficial for diabetic nephropathy (DN). A meta-analysis was conducted to assess the additive effect of pentoxifylline and its safety among patients with type 2 DN under blockade of angiotensin system.
Data sources
Relevant studies were searched from PubMed, CBM, EMBASE, CENTRAL and Cochrane renal group specialized register.
Selection criteria
All RCTs that compared the benefits and harms of pentoxifylline and ACEI/ARB with ACEI/ARB alone for DN were included.
Data extraction and analysis
Pertinent data were extracted independently by two authors. Meta-analyses were performed when more than one study provided data on a comparable outcome. Standard mean differences (SMDs) for proteinuria and albuminuria, mean differences (MDs) for systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, serum creatinine (Scr), creatinine clearance (CrCl) and urine tumor necrosis factor-alpha (UTNF-α), 95 % confidence intervals (CIs) were calculated, and heterogeneity was assessed with the I 2 test. Adverse effects were assessed using descriptive techniques.
Results
Eight studies including 587 patients with a median duration of 5 months were identified. Compared with ACEI/ARB alone, the combination of PTF and ACEI/ARB significantly reduced proteinuria (SMD 0.76, 95 % CI 0.52–0.99), albuminuria (SMD 0.36, 95 % CI 0.12–0.59) and UTNF-α (MD 1.56 ng/g, 95 % CI 0.09–3.03). However, no statistically significant changes were observed for SBP, DBP, HbA1c, Scr and CrCl. The most frequent adverse effects in patients treated with PTF were gastrointestinal symptoms (28/298) and dizziness (7/298), but in most cases, these symptoms were mild, only six participants withdrew due to intractable nausea and vomiting.
Conclusions
Pentoxifylline can significantly provide additive antiproteinuric effect independent from the decrease in BP or improvement in glycemic control in DN patients under blockade of angiotensin system. Further large, multicenter, high-quality studies with long duration are necessary to prove whether it really has renoprotective effects in this patient population.
Similar content being viewed by others
References
Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523
Haffner SM, Lehto S, Rönnemaa T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234
Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Socm Nephrol 24(2):302–308
Parving HH (1996) Initiation and progression of diabetic nephropathy. N Engl J Med 335(22):1682–1683
Kdigo BP (2012) Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2:337–414
American Diabetes Association (2014) Standards of medical care in diabetes 2014. Diab Care 37(Suppl 1):S14–S80
Perkins BA, Ficociello LH, Silva KH et al (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348(23):2285–2293
National Kidney Foundation (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886
Parving HH, Brenner BM, Investigators ALTITUDE et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213
Fried LF, Emanuele N, Investigators VANEPHRON-D et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903
De Sanctis MT, Cesarone MR, Belcaro G et al (2002) Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial–walking distance and microcirculation. Angiology 53(Suppl 1):S7–S12
Abdel-Salam OM, Baiuomy AR, El-Shenawy SM et al (2003) The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 47(4):331–340
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M et al (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7(6):327–340
Navarro JF, Mora C, Maca M et al (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42(1):53–61
Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34(1):50–97
Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33(3):458–463
McCormick BB, Sydor A, Akbari A et al (2008) The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 52(3):454–463
Shan D, Wu HM, Yuan QY et al (2012) Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 15(2):CD006800
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
Harmankaya O, Seber S, Yilmaz M (2003) Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25(3):465–470
Navarro JF, Mora C, Muros M et al (2003) Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis 42(2):264–270
Navarro JF, Mora C, Muros M et al (2005) Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 16(7):2119–2126
Roozbeh J, Banihashemi MA, Ghezlou M et al (2010) Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail 32(2):172–178
Oliaei F, Hushmand S, Khafri S et al (2011) Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian J Intern Med 2(4):309–313
Jin-Lei LV, Liu-Qing LV, Yi SHAO et al (2012) Valsartan combined with pentoxifylline in treatment of diabetic retinopathy and diabetic Nephropathy. Rec Adv Ophthalmol 32(10):945–948
Ghorbani A, Omidvar B, Beladi-Mousavi SS et al (2012) The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 32(6):790–796
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M et al (2015) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 26(1):220–229
Perkins RM, Aboudara MC, Uy AL et al (2009) Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 53(4):606–616
Goicoechea M, García de Vinuesa S, Quiroga B et al (2012) Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 25(6):969–975
Dávila-Esqueda ME, Martínez-Morales F (2004) Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat. Exp Diabesity Res 5(4):245–251
Chen YM, Lin SL, Chiang WC et al (2006) Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 69:1410–1415
Dalla Vestra M, Mussap M, Gallina P et al (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16(Suppl 1):S78–S82
Ortiz A, González-Cuadrado R, Sharma M et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34
Doherty GM, Jensen JC, Alexander HR et al (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110(2):192–198
Acknowledgments
This analysis was supported by a grant from National Natural Science Foundation of China, the category of Funding belonged to Youth Science Fund Project, and the project number was 81200539.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tian, ML., Shen, Y., Sun, ZL. et al. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol 47, 815–822 (2015). https://doi.org/10.1007/s11255-015-0968-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-015-0968-2